Ingersoll Rand Inc.
IR · NYSE
Company research
Ingersoll Rand Inc. (NYSE: IR) is a global industrial leader headquartered in Davidson, North Carolina, with roots tracing back to 1859, providing mission-critical flow creation and industrial solutions to customers across the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates through two segments — Industrial Technologies and Services (ITS), which designs, manufactures, and services air and gas compression, vacuum, blower, power tools, and lifting equipment under brands such as Ingersoll Rand, Gardner Denver, CompAir, and Nash; and Precision and Science Technologies (PST), which focuses on highly specialized pumps, fluid management systems, and gas compression solutions serving medical, life sciences, water treatment, chemical processing, energy, and food and beverage markets under brands including Milton Roy, Haskel, and Seepex. With approximately 21,000 employees, over 80 respected brands, and a market capitalization of approximately $30 billion, Ingersoll Rand generates around $7.65 billion in annual revenue, benefiting from a resilient business model that combines capital equipment sales with a high-margin aftermarket and services stream accounting for roughly 40% of total sales. Under CEO Vicente Reynal, the company continues to pursue strategic acquisitions — most notably the $2.325 billion ILC Dover deal — to expand its presence in life sciences and pharmaceuticals, while driving margin improvement through its proprietary Ingersoll Rand Excellence (IRX) operating system.
Research reports
FactorsToday (independent Equity Research Platform) · June 26, 2026Ingersoll Rand Inc. (NYSE: IR) — The Margins Doubled, the Returns Didn’t: A Brilliant Operator Earning Its Cost of Capital
Extensive fundamental deep-dive concluding IR is a superb operator with doubled operating and EBITDA margins, strong free cash flow conversion, and a fortress balance sheet, but earning only ~6–8% full-capital ROIC around its cost of capital as growth is driven largely by goodwill-heavy M&A rather than organic volume, which has been negative in 2024–2025. The report’s stated stance is HOLD/fairly valued (accumulate only on weakness into the high-$50s–$60s), highlighting key risks around continued weak organic volume, value-neutral capital allocation, and the possibility of further large-deal impairments like ILC Dover, while noting a potential upside case if organic growth re-accelerates with high incremental margins and deal-level returns demonstrably above WACC.
StockStory (independent Equity Research Site, “StockStory Analyst Team”) · March 29, 2026Ingersoll Rand (IR) Research Report: Q4 CY2025 UpdateQ4 2025 results report framing IR as an “Underperform” name: revenue up 10.1% year-on-year to 2.09 billion (beating estimates by 2.6%), adjusted EPS of 0.96 vs. 0.90 consensus (6.6% beat), with solid gross and operating margins and strong free cash flow, but only mediocre 7.3% annualized revenue growth over five years and slower 5.5% growth over the last two years. The analysts emphasize that organic demand has slowed, ROIC is modest relative to top industrial peers, and they “aren’t fans” of IR at current valuation despite a one-year Street price target of about 102.73 versus a roughly 79 share price, advising caution and indicating they prefer higher-quality alternatives with better earnings growth, with key risks including decelerating revenue growth, industrial cycle sensitivity, and limited upside from current levels.